Navigation Links
Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene
Date:10/26/2009

of siRNA to other target tissues including the eye, ear, lung, spinal cord and brain.

In addition to PF-4523655, Quark's current clinical pipeline includes QPI-1002, the first systemically administered siRNA drug in human clinical trials, developed by Quark for the prevention of acute kidney injury (AKI) following major cardiovascular surgery and the prophylaxis of delayed graft function after kidney transplantation. Quark has licenses from Silence Therapeutics and from Alnylam Pharmaceuticals for the structure of these products.

QPI-1007, a siRNA that utilizes a proprietary structure developed by Quark, is being evaluated in advanced IND-enabling preclinical studies as a neuroprotective agent in eye diseases. In addition, Quark has a broad pipeline of siRNA drug candidates based on novel structures developed internally. The Company expects to utilize the structures to develop additional RNAi drug candidates.

Quark is headquartered in Fremont, California and operates research and development facilities in Boulder, Colorado and Ness-Ziona, Israel. Additional information is available at www.quarkpharma.com.

    Quark Pharmaceuticals, Inc.         The Ruth Group (investors / media)
    Juliana Friedman                    Sara Ephraim / Janine McCargo
    +972 89 30 5111                     (646) 536-7002 / 7033
    jfriedman@quarkpharma.com           sephraim@theruthgroup.com
                                        jmccargo@theruthgroup.com

SOURCE Quark Pharmaceuticals, Inc.


'/>"/>
SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
10. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
11. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is investigating ... Inc. ("Advaxis" or the "Company") (NASDAQ: ADXS ... duties to shareholders. On January 21, 2015, ... that Advaxis had misrepresented the clinical data for its ...
(Date:1/23/2015)... 23, 2015  HyGreen, Inc., a leader in hand hygiene ... RCA Medical, a subsidiary of Ascendis Health Limited, in ... Each year, hundreds of millions of patients around the ... are transmitted from patient to patient via the unwashed ...
(Date:1/23/2015)... , Jan. 23, 2015  iMD Companies, Inc. (ICBU) has repositioned ... market share and grab a foothold in the hydroponic, hemp ... capabilities and a presence in the sector, and recently partnering ... growth of hemp and medical marijuana, iMD is committing to ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2HyGreen Partners with RCA Medical in Johannesburg, South Africa 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2
... Ill., April 19, 2011 Sysmex, a global ... systems technology, announced today an amended distributorship agreement ... automatically renews for up to four successive one-year ... including the Sysmex pocH-100 i™ , Sysmex KX-21N™, ...
... Premier Research Group Limited announces the re-branding of ... Research Company. With the continued growth in clinical development ... the medical device industry, Premier Research recognises this sector ... D-TARGET was founded in 1997 and acquired ...
Cached Medicine Technology:Sysmex America Signs Distributorship Agreement With LABSCO 2Premier Research Re-brands its Medical Device Business Unit to D-TARGET 2
(Date:1/22/2015)... 22, 2015 Payday lending practices in ... and cause financial distress to the states that permit ... Howard University’s Center on Race and Wealth. , While ... activity, payday loans at the same time substantially depress ...
(Date:1/22/2015)... 2015 As interest in the value of ... momentum worldwide, Rev. Eric J. Hall , president and ... (HCCN), will be the keynote speaker on January 27 at ... health system. , The conference, “Hope and Resilience: Innovative and ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting ... auto insurance policy . , Some types of vehicles cannot ... the newly released blog post to see if their vehicle qualifies ... vehicles are some of the cars that cannot be covered by ...
(Date:1/22/2015)... 22, 2015 Step into a macabre ... Science Museum of Virginia. Wicked Plants, the Museum’s latest ... unearths 75 poisonous, carnivorous and diabolical plants inside of ... to uncover the biochemical, physical and neurological processes between ...
(Date:12/26/2014)... The US represents the largest market for CRC across the ... that sales of branded therapies were $2.23 billion. The US ... of the disease, high drug treatment rate, and higher drug ... of CRC therapies over the forecast period will be driven ...
Breaking Medicine News(10 mins):Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... researchers have identified the first biomarker of graft-versus-host disease ... blood test that should solve a treatment dilemma facing ... marrow transplants. The biomarker also makes it possible to ... graft-versus-host disease, or GVHD. GVHD is a serious, ...
... continue climbing to exhaustion may be the only determinant of ... the University of Granada, the objective of which is to ... of sport, shows this to be the case. ... fat percentage and grip strength. Furthermore, existing research was based ...
... CT, ultrasound imaging and MRI, doctors have long been able ... patient,s body, and now a Texas A&M University mathematician is ... , The professor, Peter Kuchment, a leading researcher in mathematical ... process for detecting cancer and many other diseases. , When ...
... Researchers ... working to reduce the radiation exposure associated with CT imaging. A study featured on the ... cancer from CT imaging. , ... Loma Linda, CA (Vocus) January 7, 2010 -- Researchers from the department of radiology and ...
... ... ... College of American Pathologists (CAP) released the new CAP electronic Cancer Checklists (CAP eCC)—the XML ... enhance and advance cancer reporting., , , , ,The latest CAP eCC release contains all ...
... ... , ... 8, 2010 -- After more than 20 years with very little innovation, the world of ... tool for cast removal. , , , , ,With an operating sound level just above ...
Cached Medicine News:Health News:Blood test could improve graft-versus-host disease treatment 2Health News:Blood test could improve graft-versus-host disease treatment 3Health News:How high can a climber go? 2Health News:Texas A&M prof working on new ways to see through the human body 2Health News:New Low Dose CT Protocols for Stone Detection may Hold Key to Reducing Cancer Risk from Radiation 2Health News:New Low Dose CT Protocols for Stone Detection may Hold Key to Reducing Cancer Risk from Radiation 3Health News:College of American Pathologists Releases New Updated CAP Electronic Cancer Checklist (CAP eCC) 2Health News:College of American Pathologists Releases New Updated CAP Electronic Cancer Checklist (CAP eCC) 3Health News:College of American Pathologists Releases New Updated CAP Electronic Cancer Checklist (CAP eCC) 4Health News:New 'Kid-Friendly' Cast Removal Tool Now at Sanford 2
Landolt hypophysectomie instrument, spoon, bayonet-shaped, flexible....
Cushing pituitary scoop, malleable, silver-plated....
... Cougar is an Anterior Spinal Implant system. ... approximating that of cortical bone. The result ... requirements of anterior column support, while optimizing ... sharing design. Incorporates an anatomic design with ...
... The Stackable Cage System provides anterior column ... total vertebrectomies from T1 to L5. The ... Carbon Fiber Polymer cages that are stacked ... needs. The Peek Carbon Fiber Reinforced Polymer ...
Medicine Products: